Universität zu Köln

Gill, Christian M., Aktap, Elif, Alfouzan, Wadha, Bourassa, Lori, Brink, Adrian, Burnham, Carey-Ann D., Canton, Rafael, Carmeli, Yehuda, Falcone, Marco, Kiffer, Carlos, Marchese, Anna ORCID: 0000-0002-3188-3518, Martinez, Octavio, Pournaras, Spyros, Satlin, Michael, Seifert, Harald, Thabit, Abrar K., Thomson, Kenneth S., Villegas, Maria Virginia and Nicolau, David P. (2021). The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis., 40 (12). S. 2533 - 2542. NEW YORK: SPRINGER. ISSN 1435-4373

Full text not available from this repository.

Abstract

The cephalosporin-beta-lactamase-inhibitor-combinations, ceftolozane/tazobactam and ceftazidime/avibactam, have revolutionized treatment of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). A contemporary assessment of their in vitro potency against a global CR-PA collection and an assessment of carbapenemase diversity are warranted. Isolates determined as CR-PA by the submitting site were collected from 2019-2021 (17 centers in 12 countries) during the ERACE-PA Global Surveillance Program. Broth microdilution MICs were assessed per CLSI standards for ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime, and cefepime. Phenotypic carbapenemase testing was conducted (modified carbapenem inactivation method (mCIM)). mCIM positive isolates underwent genotypic carbapenemase testing using the CarbaR, the CarbaR NxG, or whole genome sequencing. The MIC50/90 was reported as well as percent susceptible (CLSI and EUCAST interpretation). Of the 807 isolates, 265 (33%) tested carbapenemase-positive phenotypically. Of these, 228 (86%) were genotypically positive for a carbapenemase with the most common being VIM followed by GES. In the entire cohort of CR-PA, ceftolozane/tazobactam and ceftazidime/avibactam had MIC50/90 values of 2/ > 64 and 4/64 mg/L, respectively. Ceftazidime/avibactam was the most active agent with 72% susceptibility per CLSI compared with 63% for ceftolozane/tazobactam. For comparison, 46% of CR-PA were susceptible to ceftazidime and cefepime. Against carbapenemase-negative isolates, 88 and 91% of isolates were susceptible to ceftolozane/tazobactam and ceftazidime/avibactam, respectively. Ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against carbapenem-resistant P. aeruginosa, particularly in the absence of carbapenemases. The contemporary ERACE-PA Global Program cohort with 33% carbapenemase positivity including diverse enzymology will be useful to assess therapeutic options in these clinically challenging organisms with limited therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gill, Christian M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Aktap, Elif UNSPECIFIED UNSPECIFIED UNSPECIFIED Alfouzan, Wadha UNSPECIFIED UNSPECIFIED UNSPECIFIED Bourassa, Lori UNSPECIFIED UNSPECIFIED UNSPECIFIED Brink, Adrian UNSPECIFIED UNSPECIFIED UNSPECIFIED Burnham, Carey-Ann D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Canton, Rafael UNSPECIFIED UNSPECIFIED UNSPECIFIED Carmeli, Yehuda UNSPECIFIED UNSPECIFIED UNSPECIFIED Falcone, Marco UNSPECIFIED UNSPECIFIED UNSPECIFIED Kiffer, Carlos UNSPECIFIED UNSPECIFIED UNSPECIFIED Marchese, Anna UNSPECIFIED orcid.org/0000-0002-3188-3518 UNSPECIFIED Martinez, Octavio UNSPECIFIED UNSPECIFIED UNSPECIFIED Pournaras, Spyros UNSPECIFIED UNSPECIFIED UNSPECIFIED Satlin, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Seifert, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED Thabit, Abrar K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thomson, Kenneth S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Villegas, Maria Virginia UNSPECIFIED UNSPECIFIED UNSPECIFIED Nicolau, David P. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-605721
DOI:	10.1007/s10096-021-04308-0
Journal or Publication Title:	Eur. J. Clin. Microbiol. Infect. Dis.
Volume:	40
Number:	12
Page Range:	S. 2533 - 2542
Date:	2021
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1435-4373
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ENTEROBACTERIACEAE; INFECTIONS; TAZOBACTAM; AVIBACTAM Multiple languages Infectious Diseases; Microbiology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60572